USPTO Registration Examination (Patent Bar)

# USPTO Patent Bar Study Notes
## GROUNDED — generated from real us_cases (US corpus). Citations are real DB records; holdings extracted from opinions.

---

## MPEP Chapter 2100 – Patentability

### 35 USC 101 – Subject Matter Eligibility

**Core Doctrine: Products of Nature Exception**
- **Holding**: A naturally occurring DNA segment is not patent-eligible merely because it has been isolated from the genome. Isolation alone, without creating a fundamentally new molecule, does not satisfy § 101.
- **Real Case**: *Association for Molecular Pathology v. Myriad Genetics, Inc.*, 569 U.S. 576 (2013, Supreme Court of the United States)
- **Citation**: 569 U.S. 576
- **Key Facts**: Myriad discovered the BRCA1 and BRCA2 genes and attempted to patent isolated DNA segments. The Supreme Court held that "a naturally occurring DNA segment is a product of nature and not patent eligible merely because it has been isolated."
- **Practical Application**: Claims must demonstrate new composition or function, not just isolation of naturally occurring sequences.

**cDNA Patent Eligibility**
- **Holding**: Complementary DNA (cDNA) is patent-eligible because it is a synthetic creation—introns are removed during laboratory synthesis, making it non-naturally occurring.
- **Real Case**: *Association for Molecular Pathology v. Myriad Genetics, Inc.*, 569 U.S. 576 (2013, Supreme Court of the United States)
- **Citation**: 569 U.S. 576
- **Key Distinction**: The opinion explicitly states: "cDNA does not present the same obstacles to patentability as naturally occurring, isolated DNA segments... the lab technician unquestionably creates something new when cDNA is made."
- **Exam Tip**: cDNA claims often pass § 101 because the exon-only sequence does not exist in nature.

**Genetically Modified Organisms (Non-Natural Compositions)**
- **Holding**: A non-naturally occurring manufacture or composition of matter—such as a bacterium with added plasmids having a distinctive character and use—is patent-eligible under § 101.
- **Real Case**: *Diamond v. Chakrabarty*, 447 U.S. 303 (1980, Supreme Court of the United States)
- **Citation**: 447 U.S. 303
- **Key Facts**: Scientist created a bacterium by adding four plasmids, enabling it to degrade crude oil. The bacterium had "markedly different characteristics from any found in nature."
- **Rule**: Non-naturally occurring products with new properties and uses are patent-eligible, even if based on natural organisms.

---

## General Patent Law Framework

### Filing and Application Structure

**Patent Applications must contain statutory subject matter under 35 USC 101:**
- Utility patents: new and useful processes, machines, manufactures, or compositions of matter
- Design patents: new ornamental designs for articles of manufacture
- Plant patents: asexually reproduced plants

**From USPTO case law precedent**: Extensive research effort, while valuable, does not automatically confer patent eligibility. The patent must claim a concrete, new composition or process with inventive results.

---

## Key Concepts for Exam Preparation

### Alice/Mayo Test (Abstract Idea Framework)
While specific Alice and Mayo cases were not returned in full from the database, the framework is foundational:
- **Step 1**: Is the claim directed to a law of nature, natural phenomenon, or abstract idea?
- **Step 2**: If yes, does the claim contain an "inventive concept" that transforms it into patent-eligible matter?

### Doctrine of Equivalents & Claim Scope
Patent claims must be definite and must not be so broad that they effectively claim unmodified natural phenomena.

---

## Critical Distinctions

| Topic | Holding | Authority |
|-------|---------|-----------|
| **Isolated Natural DNA** | NOT patent-eligible | 569 U.S. 576 (Myriad) |
| **cDNA (synthetic)** | Patent-eligible | 569 U.S. 576 (Myriad) |
| **Genetically Modified Organism** | Patent-eligible if non-naturally occurring and useful | 447 U.S. 303 (Chakrabarty) |
| **Mere Discovery of Natural Sequence** | Insufficient for § 101 | 569 U.S. 576 (Myriad) |

---

## Exam-Focused Rules

1. **Always assess whether the claimed composition is naturally occurring.** If yes, ask: Has it been fundamentally altered in a way that creates new properties?
2. **Isolation without modification does not = patentability.** Chemical bonding changes alone do not render DNA patent-eligible.
3. **Apply the Chakrabarty standard**: Does the composition have "a distinctive name, character, and use" distinct from nature?
4. **cDNA always gets favorable treatment** because synthetic splicing is not a natural process.
5. **Research effort ≠ Patentability**. The effort to discover something does not make it patentable—only the end product matters.

---

## Key MPEP Sections to Cross-Reference
- MPEP 2106: Subject Matter Eligibility
- MPEP 2106.02: "Products of Nature"
- MPEP 2106.04: Abstract Ideas
- MPEP 2102: Specification Requirements (written description, enablement)